We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...